Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Mirati Therapeutics Inc.)"
Count: 65
Selected: 0
| NCT ID | Title |
|---|
| NCT05840510 | Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) | ||
| NCT05868356 | A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib | ||
| NCT05853575 | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | ||
| NCT05737706 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | ||
| NCT05609578 | Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation | ||
| NCT05578092 | A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | ||
| NCT05255276 | PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor. | ||
| NCT05245500 | Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion | ||
| NCT05178888 | Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16) | ||
| NCT05162443 | Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation | ||
| NCT04975256 | Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) | ||
| NCT04935112 | A Study to Explore the Effect of Acid-reducing Agents | ||
| NCT04887870 | Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study | ||
| NCT04887194 | PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates | ||
| NCT04800614 | A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib | ||
| NCT04793958 | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | ||
| NCT04772612 | A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib | ||
| NCT04685135 | Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | ||
| NCT04613596 | Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients KRAS G12C Mutation KRYSTAL-7 | ||
| NCT04518046 | Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies | ||
| NCT04330664 | Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) | ||
| NCT03906071 | Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer | ||
| NCT03785249 | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | ||
| NCT03680521 | Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma | ||
| NCT03606174 | Study of Sitravatinib + PD-(L)1 Checkpoint Inhibitor Regimens in Urothelial Carcinoma | ||
| NCT02954991 | Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer | ||
| NCT02805660 | Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC | ||
| NCT02544633 | Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET | ||
| NCT02236195 | Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes | ||
| NCT02219711 | Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer | ||
| NCT02117245 | Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers | ||
| NCT02018926 | Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS | ||
| NCT01930006 | Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State | ||
| NCT00975767 | A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer | ||
| NCT00697632 | Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies | ||
| NCT00679133 | Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies | ||
| NCT00666497 | Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | ||
| NCT00543582 | MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma | ||
| NCT00511576 | Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors | ||
| NCT00431873 | A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia | ||
| NCT00374296 | MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease | ||
| NCT00372437 | A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine | ||
| NCT00359086 | Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma | ||
| NCT00358982 | Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma | ||
| NCT00324220 | A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia | ||
| NCT00324194 | A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes | ||
| NCT00324129 | A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes | ||
| NCT00323934 | Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | ||
| NCT05375994 | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients | ||
| NCT05673187 | Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status |
